Algorithm Predicts Efficacy of Cancer Treatment

Immunotherapies are promising new cancer treatments that tend to be less toxic than traditional therapies. However, patients may not always respond to therapy or they may experience significant adverse events.
 
To address these challenges, researchers recently developed a mathematical model that can accurately predict whether a patient with cancer will respond to immunotherapy, according to a study published by Nature.
 
Scientists have been searching for a way to determine whether patients will respond to new checkpoint inhibitors and to understand the characteristics underlying why the therapy was successful.
 
The novel algorithm characterizes the tumor's evolution and its interactions with the immune system, according to the study. The authors said that this mathematical algorithm can more accurately predict how cancer will respond to immunotherapy compared with currently used biomarkers.
 
"We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors," said senior author Benjamin Greenbaum, PhD. "This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors."
 
The model may also help discover new therapies that can target the immune system or vaccines for patients who do not respond to immunotherapy, according to the study.
 
Data from patients with melanoma and lung cancer who received immunotherapy treatment were compiled to create the model. The system can track immune response to the drugs by focusing on neoantigens.
 
The authors note that neoantigens have the potential to be an immunotherapy target and can be useful for patients with drug resistant disease. The neoantigens may be critical to understanding why sometimes immunotherapy results in autoimmune side effects, according to the authors.
 
Specifically, the mathematical model can predict immune response in patients with pancreatic cancer.
 
These models may result in more accurate therapy and prevent potentially dangerous adverse events. Additionally, it could reduce drug costs, as the model could prevent unnecessary treatments, according to the authors. 
 
"This research represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response," said corresponding author Vinod P. Balachandran, MD. 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Patients with multiple sclerosis who eat healthy could reduce their risk of severe disability by 20%.
Only 21% of HIV-positive individuals visited a health care provider within 2 weeks of release from jail or prison.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.